Episode 400: 408. CME Obesity and MASH

Episode 400: 408. CME Obesity and MASH

  • GLP1 drugs work but they likely need lifestyle modifications


  • No convincing evidence GLP1 cause thyroid cancer in humans BUT contraindication if family history exist


  • Stopping therapy usually results in weight gain


  • Insurance coverage for weight loss is limited and variable


  • Semaglutide for type 2 diabetes max dose is 2.0 mg weekly Semaglutide for weight loss has a goal dose of 2.4 mg weekly
  • Diagnose steatotic liver disease with imaging and 1 metabolic risk factor (or biopsy)


  • After diagnosis check FIB-4:
    • Low risk, continue to monitor with FIB-4 every 2-3yrs
    • Intermediate risk, order VCTE and consider referral if >F1
    • High risk order a VCTE and referral (20% end with SLD)


  • 2 FDA approved medications for liver fibrosis are not cheap, expect insurance push back


Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(401)

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
aamukahvilla
psykopodiaa-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
meditaatiot-suomeksi
tiedenaiset-podcast
rss-pt-paahtio
katilon-kahvitunti
voi-hyvin-meditaatiot-2
rss-hereilla
rss-uplevel-by-sonja-hannus
hippokrateen-vastaanotolla
rss-rampaseksia
rss-rentoudu-podcast-rentoutumiseen-hanna-viljanmaa
rss-adama-mindful-hetki
rss-vapaudu-voimaasi
rss-sanelunpurku-podcast
rakkaudella-karita
selviytyjat-tarinoita-elamasta
rss-mighty-finland-podcast